(ARNT) Transcriptional Co-Regulator Complex: Effects on Estrogen and Hypoxia Signaling

Total Page:16

File Type:pdf, Size:1020Kb

(ARNT) Transcriptional Co-Regulator Complex: Effects on Estrogen and Hypoxia Signaling The aryl hydrocarbon receptor nuclear translocator (ARNT) transcriptional co-regulator complex: Effects on estrogen and hypoxia signaling by Mark Labrecque B.Sc., University of British Columbia, 2007 Thesis Submitted in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy in the Doctor of Philosophy Program Faculty of Health Sciences Mark Labrecque 2016 SIMON FRASER UNIVERSITY Summer 2016 Approval Name: Mark Labrecque Degree: Doctor of Philosophy Title: The aryl hydrocarbon receptor nuclear translocator (ARNT) transcriptional co-regulator complex: Effects on estrogen and hypoxia signaling Examining Committee: Chair: Dr. Tim Takaro Professor Dr. Timothy Beischlag Senior Supervisor Associate Professor Dr. Frank Lee Supervisor Associate Professor Dr. Gratien Prefontaine Supervisor Associate Professor Dr. Christopher Beh Internal Examiner Associate Professor Department of Molecular Biology and Biochemistry Dr. Judy Wong External Examiner Associate Professor Faculty of Pharmaceutical Sciences University of British Columbia Date Defended/Approved: August 11, 2016 ii Abstract The basic Helix-Loop-Helix/PER-ARNT-SIM (bHLH-PAS) domain family of proteins mediates cellular responses to a variety of stimuli. The bHLH-PAS proteins are heterodimeric transcription factors that are further sub-classified into sensory and aryl hydrocarbon receptor nuclear translocator (ARNT) proteins. The ARNT protein is constitutively expressed and heterodimerizes with hypoxia-inducible factors (HIFs) to mediate oxygen-sensing mechanisms and heterodimerizes with the aryl hydrocarbon receptor (AHR) to combat environmental contaminant exposure. Firstly, a reciprocal disruption relationship exists between AHR ligands, like 2,3,7,8-tetrachlorodibenzo-p- dioxin (TCDD) and estrogen receptor (ER) ligands, like 17β-estradiol (E2). Ligand-bound ER tethers to the AHR/ARNT transcription factor complex and represses TCDD- inducible gene transcription. However, the tethering paradigm and molecular mechanisms employed by AHR and ARNT at ER-regulated genes remains to be determined. Secondly, thyroid hormone receptor/retinoblastoma-interacting protein 230 (TRIP230) interacts with ARNT and is a coactivator required for hypoxia-regulated transcription. The retinoblastoma protein (Rb) is a negative regulator of the cell cycle and also negatively regulates TRIP230 coactivator potential. Thus, Rb may influence ARNT transcription factor functions via TRIP230. Rb-loss in many solid tumours directly precedes the activation of HIF-regulated genes and correlates with increased angiogenesis and metastasis. As most solid tumours contain regions of hypoxia and only correlative data between HIF/ARNT activity and Rb-loss has been gathered, we have identified a need to rigorously examine the role of Rb-loss in concert with hypoxia in breast and prostate cancer models. In this thesis, I used siRNA technology to knockdown ARNT and AHR expression and found that TCDD-mediated disruption of ER-signalling is AHR-dependent and that ARNT is a coactivator in MCF7 cells and a corepressor in ECC1 cells. Additionally, I used siRNAs and shRNA technology in concert with microarray analysis in LNCaP prostate cancer cells and MCF7 breast cancer cells to delineate the role of the ARNT-TRIP230-Rb transcriptional complex in hypoxia- regulated transcription. I found that Rb-depletion in conjunction with hypoxia exacerbates HIF1-mediated transcription and promotes a more invasive and late stage phenotype in both breast and prostate cancer models. The molecular mechanisms and gene pathways described herein should prove useful for developing chemotherapies for late stage breast and prostate cancers. Keywords: ARNT; AHR; ER; TRIP230, Retinoblastoma protein; HIF1 iii Dedication For my wife, Alexa, and our son, Lincoln, Thank you for all the love and support and for always bringing a smile to my face iv Acknowledgements My journey at SFU has been long, interesting and slightly unexpected and it would not have been possible without the support and guidance from several key individuals. I would like to thank my senior supervisor, Dr. Timothy Beischlag, for giving me the opportunity to develop as a scientist and for sparking a curiosity that has led to both personal and intellectual growth. I am grateful for his mentorship, leadership and encouragement; my time as a graduate student under his guidance has profoundly changed my life. I am indebted to my supervisory committee, Dr. Gratien Prefontaine and Dr. Frank Lee, for their valuable feedback over the years and for helping me stay on track. I would also like to extend my thanks to my internal examiner, Dr. Christopher Beh, and my external examiner, Dr Judy Wong, for taking the time to read my thesis and for sitting on my examining committee. To all the past and present members of the Beischlag Lab, thank you for making the lab an enjoyable and productive environment. Kevin Tam, Julienne Jagdeo, Mandeep Takhar, Lillian Wong, Alex Reers, Stephanie Santacruz and Rebecca Nason, thank you for your support and for all the hardwork that has made several of our publications a reality. To Shabnam Massah and Sam Khakshour, thank you for your friendship and for allowing me to collaborate with you on interesting research projects that have enriched my time as a graduate student at SFU. To Dr. Michael Cox and his team at the Vancouver Prostate Centre, and to Dr. Kevin Bennewith and his team at the BC Cancer Research Centre, thank you for all your research insights, for being so generous with your time and for the mentorship and learning opportunities that were provided. I will forever cherish my graduate student experiences at your world-class organizations. Lastly but most importantly, thank you to my family. My graduate student journey would not have been possible without the steadfast support of my wife, mom, dad, brother and sister. You inspire me to be a better man and to reach for the stars. This work was supported in part by graduate fellowships from Simon Fraser University and by a graduate studentship award from Prostate Cancer Canada. v Table of Contents Approval .............................................................................................................................ii Abstract ............................................................................................................................. iii Dedication .........................................................................................................................iv Acknowledgements ........................................................................................................... v Table of Contents ..............................................................................................................vi List of Tables ..................................................................................................................... x List of Figures....................................................................................................................xi List of Acronyms .............................................................................................................. xiii Chapter 1. Introduction ............................................................................................... 1 1.1. The aryl hydrocarbon receptor nuclear translocator (ARNT) family of proteins .................................................................................................................... 2 1.2. The aryl hydrocarbon receptor (AHR) ...................................................................... 5 1.2.1. Endocrine disruption and the estrogen receptor (ER) ................................. 7 1.2.2. AHR, ER and ARNT crosstalk .................................................................... 9 1.3. Carcinogenesis ...................................................................................................... 11 1.4. Tumour Microenvironment ..................................................................................... 13 1.4.1. Normoxia and Hypoxia .............................................................................. 13 1.5. Hypoxia Inducible Factors (HIFs) ........................................................................... 15 1.6. Thyroid hormone receptor/retinoblastoma-interacting protein 230 (TRIP230) ....... 16 1.6.1. TRIP230 and interactions with ARNT ....................................................... 18 1.7. The Pocket Proteins ............................................................................................... 18 1.7.1. Molecular components of Rb, p107 and p130 .......................................... 18 1.7.2. Rb and cell cycle control. .......................................................................... 19 1.7.3. Rb function in apoptosis and the DNA damage response. ....................... 22 1.7.4. Rb and cancer ........................................................................................... 24 1.8. Prostate Cancer ..................................................................................................... 25 1.8.1. The androgen receptor and roles in prostate cancer. ............................... 25 1.8.2. Neuroendocrine differentiation in prostate cancer .................................... 26 1.8.3. NED and Rb .............................................................................................. 28 1.9. Breast Cancer .......................................................................................................
Recommended publications
  • Peripheral Nervous System……………………………………………….9
    PhD School in Integrative Biomedical Research Department of Pharmacological and Biomolecular Sciences Curriculum: Neuroscience Molecular basis for the development of innovative therapies for peripheral neuropathies treatment: role and cross-regulation of the GABAergic system and neuroactive steroids SDD BIO/09 - Physiology Luca Franco Castelnovo Badge number R10402 PhD Tutor: Prof. Valerio Magnaghi PhD School Coordinator: Prof. Chiarella Sforza Academic year 2015/2016 INDEX Abstract…………………………………………………………………...page 1 Abbreviations list…………………………………………………………….....5 Introduction………………………………………………………………….....8 Peripheral nervous system……………………………………………….9 General concepts……………...……….……………………………........……..9 Sensory system and nociceptive fibers.………………..………….…………..12 Schwann cells and myelination……….……..………………...………………15 Peripheral neuropathies…….…………………………………………...26 General concepts……………………………………………………...……….26 Neuropathic pain……………………………………...……………………….27 Nerve regeneration…………………………………………………………….28 The GABAergic system………….……………………………………...32 GABA……………….…………………………………………………..……..32 GABA-A receptors…………………………………………………………….33 GABA-B receptors…………………………………………………………….42 GABAergic system in the peripheral nervous system…………………………47 Protein kinase C – type ε……………………….………………………..51 General concepts…………………………………………………….…………51 Cross-talk with allopregnanolone and GABA-A………………………………54 Neuroactive steroids…………......………………………………………57 General concepts…………………………………….…………………………57 Mechanism of action…………………………….……………………………..59 Progesterone derivatives………………………………….……………………60
    [Show full text]
  • The Rise and Fall of the Bovine Corpus Luteum
    University of Nebraska Medical Center DigitalCommons@UNMC Theses & Dissertations Graduate Studies Spring 5-6-2017 The Rise and Fall of the Bovine Corpus Luteum Heather Talbott University of Nebraska Medical Center Follow this and additional works at: https://digitalcommons.unmc.edu/etd Part of the Biochemistry Commons, Molecular Biology Commons, and the Obstetrics and Gynecology Commons Recommended Citation Talbott, Heather, "The Rise and Fall of the Bovine Corpus Luteum" (2017). Theses & Dissertations. 207. https://digitalcommons.unmc.edu/etd/207 This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It has been accepted for inclusion in Theses & Dissertations by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. THE RISE AND FALL OF THE BOVINE CORPUS LUTEUM by Heather Talbott A DISSERTATION Presented to the Faculty of the University of Nebraska Graduate College in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy Biochemistry and Molecular Biology Graduate Program Under the Supervision of Professor John S. Davis University of Nebraska Medical Center Omaha, Nebraska May, 2017 Supervisory Committee: Carol A. Casey, Ph.D. Andrea S. Cupp, Ph.D. Parmender P. Mehta, Ph.D. Justin L. Mott, Ph.D. i ACKNOWLEDGEMENTS This dissertation was supported by the Agriculture and Food Research Initiative from the USDA National Institute of Food and Agriculture (NIFA) Pre-doctoral award; University of Nebraska Medical Center Graduate Student Assistantship; University of Nebraska Medical Center Exceptional Incoming Graduate Student Award; the VA Nebraska-Western Iowa Health Care System Department of Veterans Affairs; and The Olson Center for Women’s Health, Department of Obstetrics and Gynecology, Nebraska Medical Center.
    [Show full text]
  • Progesterone Receptor Membrane Component 1 Promotes Survival of Human Breast Cancer Cells and the Growth of Xenograft Tumors
    Cancer Biology & Therapy ISSN: 1538-4047 (Print) 1555-8576 (Online) Journal homepage: http://www.tandfonline.com/loi/kcbt20 Progesterone receptor membrane component 1 promotes survival of human breast cancer cells and the growth of xenograft tumors Nicole C. Clark, Anne M. Friel, Cindy A. Pru, Ling Zhang, Toshi Shioda, Bo R. Rueda, John J. Peluso & James K. Pru To cite this article: Nicole C. Clark, Anne M. Friel, Cindy A. Pru, Ling Zhang, Toshi Shioda, Bo R. Rueda, John J. Peluso & James K. Pru (2016) Progesterone receptor membrane component 1 promotes survival of human breast cancer cells and the growth of xenograft tumors, Cancer Biology & Therapy, 17:3, 262-271, DOI: 10.1080/15384047.2016.1139240 To link to this article: http://dx.doi.org/10.1080/15384047.2016.1139240 Accepted author version posted online: 19 Jan 2016. Published online: 19 Jan 2016. Submit your article to this journal Article views: 49 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=kcbt20 Download by: [University of Connecticut] Date: 26 May 2016, At: 11:28 CANCER BIOLOGY & THERAPY 2016, VOL. 17, NO. 3, 262–271 http://dx.doi.org/10.1080/15384047.2016.1139240 RESEARCH PAPER Progesterone receptor membrane component 1 promotes survival of human breast cancer cells and the growth of xenograft tumors Nicole C. Clarka,*, Anne M. Frielb,*, Cindy A. Prua, Ling Zhangb, Toshi Shiodac, Bo R. Ruedab, John J. Pelusod, and James K. Prua aDepartment of Animal Sciences,
    [Show full text]
  • Targeting EZH2 Reactivates a Breast Cancer Subtype-Specific Anti-Metastatic Transcriptional Program
    ARTICLE DOI: 10.1038/s41467-018-04864-8 OPEN Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program Alison Hirukawa1,2, Harvey W. Smith1, Dongmei Zuo1, Catherine R. Dufour1, Paul Savage 1, Nicholas Bertos 1, Radia M. Johnson1, Tung Bui1,2, Guillaume Bourque3,4, Mark Basik5,6, Vincent Giguère 1,2,6, Morag Park1,2,6 & William J. Muller1,2,6 1234567890():,; Emerging evidence has illustrated the importance of epigenomic reprogramming in cancer, with altered post-translational modifications of histones contributing to pathogenesis. However, the contributions of histone modifiers to breast cancer progression are unclear, and how these processes vary between molecular subtypes has yet to be adequately addressed. Here we report that genetic or pharmacological targeting of the epigenetic modifier Ezh2 dramatically hinders metastatic behaviour in both a mouse model of breast cancer and patient-derived xenografts reflective of the Luminal B subtype. We further define a subtype- specific molecular mechanism whereby EZH2 maintains H3K27me3-mediated repression of the FOXC1 gene, thereby inactivating a FOXC1-driven, anti-invasive transcriptional program. We demonstrate that higher FOXC1 is predictive of favourable outcome specifically in Luminal B breast cancer patients and establish the use of EZH2 methyltransferase inhibitors as a viable strategy to block metastasis in Luminal B breast cancer, where options for targeted therapy are limited. 1 Goodman Cancer Research Centre, McGill University, Montréal, QC H3A 1A3, Canada. 2 Department of Biochemistry, McGill University, Montréal, QC H3G 1Y6, Canada. 3 McGill University, Génome Québec Innovation Centre, Montréal, QC H3A 0G1, Canada. 4 Department of Human Genetics, McGill University, Montréal, QC H3A 1A3, Canada.
    [Show full text]
  • Identification and Characterization of the Forkhead Box
    IDENTIFICATION AND CHARACTERIZATION OF THE FORKHEAD BOX FAMILY OF TRANSCRIPTIONAL REGULATORS IN PARASITIC SCHISTOSOMES by MELISSA M. VARRECCHIA Submitted in partial fulfillment of the requirements for the degree of Doctor of philosophy Department of Biology CASE WESTERN RESERVE UNIVERSITY August 2017 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the dissertation of Melissa M. Varrecchia candidate for the degree of Doctor of Philosophy Committee Chair Michael F. Benard Committee Member Emmitt R. Jolly Committee Member Christopher A. Cullis Committee Member Claudia M. Mizutani Committee Member Brian M. McDermott Date of Defense June 6, 2017 *We also certify that written approval has been obtained for any proprietary material contained therein. ii Dedication I would like to dedicate this dissertation to my Mom and Dad. Mom, thank you for your endless love, support and encouragement throughout the years. Dad, I miss you and I know that you are with me always, cheering me on in spirit. iii Table of Contents Table of Contents………………………………………………………………………...1 List of Tables……………………………………………………………………………..6 List of Figures…………………………………………………………………………....8 Acknowledgements…………………………………………………………………..…11 List of Abbreviations…………………………………………………………………...13 Abstract…………………………………………………………………………………15 Chapter 1: Introduction………………………………………………………………..17 1.1 Schistosomiasis………………………………………………………………17 1.2 Pathogenesis and treatment…………………………………………………..18 1.3 Schistosome life cycle………………………………………………………..20 1.4 Schistosome morphology
    [Show full text]
  • Research Progress on the Forkhead Box C1
    www.impactjournals.com/oncotarget/ Oncotarget, 2018, Vol. 9, (No. 15), pp: 12471-12478 Review Research progress on the forkhead box C1 Jinhua Wang1,2, Wan Li2, Xiangjin Zheng2, Xiaocong Pang2 and Guanhua Du1,2 1The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing 100050, China 2Key Laboratory of Drug Target Research and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China Correspondence to: Jinhua Wang, email: [email protected] Guanhua Du, email: [email protected] Keywords: FOX family; FOXC1; cancer; drug resistance; stem cell Received: July 29, 2017 Accepted: November 01, 2017 Published: November 20, 2017 Copyright: Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT FOXC1 is a vital member of FOX families which play important roles in biological processes including proliferation, differentiation, apoptosis, migration, invasion, metabolism, and longevity. Here we are focusing on roles of FOXC1 and their mechanisms in cancers. FOXC1 promoted progress of many cancers, such as breast cancer (especially basal-like breast cancer), hepatocellular carcinoma, gastric cancer and so on. FOXC1 was also found to be associated with drug resistance of cancers. FOXC1 promoted metastasis of cancers by increasing expression of MMP7, NEDD9 and Snail. Proliferation and invasion of cancers were increased by FOXC1 by mediating NF-κB, MST1R and KLF4 expression. FOXC1 was associated with development by regulating expression of FGF19 and MSX1.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene
    Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A.
    [Show full text]
  • Mechanisms Acting on Hedgehog-Gli Pathway and Their Therapeutic Potential
    From the Department of Biosciences and Nutrition Karolinska Institutet, Stockholm, Sweden MECHANISMS ACTING ON HEDGEHOG-GLI PATHWAY AND THEIR THERAPEUTIC POTENTIAL Ani Azatyan Stockholm 2020 All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. Printed by Universitetsservice US-AB © Ani Azatyan, 2020 ISBN 978-91-7831-880-3 Mechanisms acting on Hedgehog-GLI pathway and their therapeutic potential THESIS FOR DOCTORAL DEGREE (Ph.D.) By Ani Azatyan Principal Supervisor: Opponent: Prof. Peter Zaphiropoulos Prof. Matthias Lauth Karolinska Institutet Philipps-University Marburg, Germany Department of Biosciences and Nutrition Center for Tumor Biology and Immunology Co-supervisor(s): Examination Board: Prof. Karl Ekwall Doc. Ning Xu Landén Karolinska Institutet Karolinska Institutet Department of Biosciences and Nutrition Department of Medicine, Division of Dermatology Doc. Vladimir Bykov Prof. Sonia Lain Karolinska Institutet Karolinska Institutet Department of Oncology-Pathology Department of Microbiology, Tumor and Cell Biology Prof. Ann-Kristin Östlund Farrants Stockholm University Department of Molecular Biosciences “I am among those who think that science has great beauty” - Marie Curie Abstract Hedgehog signaling is crucial for diverse aspects of animal development, essential in regulating many cellular processes and is largely implicated in various forms of human cancer. However, many aspects of Hedgehog signaling are not completely understood. This thesis aims to contribute towards a better understanding of the mechanisms acting on Hedgehog-GLI signaling and explore their possible therapeutic potential. PAPER I. We demonstrate that the small molecule RITA, a p53 activator, downregulates Hedgehog signaling in human medulloblastoma and rhabdomyosarcoma cells via JNK kinase and irrespective of p53. In vitro RITA enhanced the anti-proliferative effects of the GLI antagonist GANT61.
    [Show full text]
  • Human Chorionic Gonadotropin Increases Serum Progesterone, Number of Corpora Lutea and Angiogenic Factors in Pregnant Sheep
    REPRODUCTIONRESEARCH Human chorionic gonadotropin increases serum progesterone, number of corpora lutea and angiogenic factors in pregnant sheep Megan P T Coleson*, Nicole S Sanchez*, Amanda K Ashley, Timothy T Ross and Ryan L Ashley Department of Animal and Range Sciences, New Mexico State University, PO Box 30003, MSC 3I, Las Cruces, New Mexico 88003, USA Correspondence should be addressed to R L Ashley; Email: [email protected] *(M P T Coleson and N S Sanchez contributed equally to this work) Abstract Early gestation is a critical period when implantation and placental vascularization are established, processes influenced by progesterone (P4). Although human chorionic gonadotropin (hCG) is not endogenously synthesized by livestock, it binds the LH receptor, stimulating P4 synthesis. We hypothesized treating pregnant ewes with hCG would increase serum P4, number of corpora lutea (CLs) and concepti, augment steroidogenic enzymes, and increase membrane P4 receptors (PAQRs) and angiogenic factors in reproductive tissues. The objective was to determine molecular alterations induced by hCG in pregnant sheep that may promote pregnancy. Ewes received either 600 IU of hCG or saline i.m. on day 4 post mating. Blood samples were collected daily from day 0 until tissue collection for serum P4 analysis. Reproductive tissues were collected on either day 13 or 25 of gestation and analyzed for PAQRs, CXCR4, proangiogenic factors and steroidogenic enzymes. Ewes receiving hCG had more CL and greater serum P4, which remained elevated. On day 25, StAR protein production decreased in CL from hCG-treated ewes while HSD3B1 was unchanged; further, expression of CXCR4 significantly increased and KDR tended to increase.
    [Show full text]
  • Human Pluripotent Stem Cell-Derived Ectomesenchymal Stromal Cells Promote More Robust Functional Recovery Than Umbilical Cord-De
    Human pluripotent stem cell-derived ectomesenchymal stromal cells promote more robust functional recovery than umbilical cord-derived mesenchymal stromal cells after hypoxic- ischaemic brain damage Jiawei Huang1,3*, Kin Pong U1,3*, Fuyuan Yang1, Zeyuan Ji1, Jiacheng Lin1,3, Zhihui Weng1, Lai Ling Tsang1,3, Tobias D Merson5, Ye Chun Ruan6, Chao Wan1,3, Gang Li2, Xiaohua Jiang1,3,4 1School of Biomedical Sciences, 2Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, PR China. 3School of Biomedical Sciences Core Laboratory, Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, PR China. 4Sichuan University – The Chinese University of Hong Kong Joint Laboratory for Reproductive Medicine, West China Second University Hospital, Sichuan University, Chengdu 610041, Sichuan, China. 5Australian Regenerative Medicine Institute, Monash University, Clayton, VIC, Australia. 6Department of Biomedical Engineering, Faculty of Engineering, The Hong Kong Polytechnic University, Hong Kong, China. Running Title: Human ectomesenchymal stromal cells promote functional recovery in a rat HIE model *Corresponding author: Prof. Xiaohua JIANG, Email: [email protected] Address: Room 409A, Lo Kwee Seong Integrated Biomedical Sciences Building, Area 39, The Chinese University of Hong Kong, Shatin. Keywords: HIE, ectomesenchymal stromal cells, brain damage, regeneration, paracrine, ERK Abstract: Aims: Hypoxic-ischaemic encephalopathy (HIE) is one of the most serious complications in neonates and infants. Mesenchymal stromal cell (MSC)-based therapy is emerging as a promising treatment avenue for HIE. However, despite its enormous potential, the clinical application of MSCs is limited by cell heterogeneity, low isolation efficiency and unpredictable effectiveness. In this study, we examined the therapeutic effects and underlying mechanisms of human pluripotent stem cell-derived ectomesenchymal stromal cells (hPSC-EMSCs) in a rat model of HIE.
    [Show full text]
  • Sox2 Promotes Malignancy in Glioblastoma by Regulating
    Volume 16 Number 3 March 2014 pp. 193–206.e25 193 www.neoplasia.com Artem D. Berezovsky*, Laila M. Poisson†, Sox2 Promotes Malignancy in ‡ ‡ David Cherba , Craig P. Webb , Glioblastoma by Regulating Andrea D. Transou*, Nancy W. Lemke*, Xin Hong*, Laura A. Hasselbach*, Susan M. Irtenkauf*, Plasticity and Astrocytic Tom Mikkelsen*,§ and Ana C. deCarvalho* Differentiation1,2 *Department of Neurosurgery, Henry Ford Hospital, Detroit, MI; †Department of Public Health Sciences, Henry Ford Hospital, Detroit, MI; ‡Program of Translational Medicine, Van Andel Research Institute, Grand Rapids, MI; §Department of Neurology, Henry Ford Hospital, Detroit, MI Abstract The high-mobility group–box transcription factor sex-determining region Y–box 2 (Sox2) is essential for the maintenance of stem cells from early development to adult tissues. Sox2 can reprogram differentiated cells into pluripotent cells in concert with other factors and is overexpressed in various cancers. In glioblastoma (GBM), Sox2 is a marker of cancer stemlike cells (CSCs) in neurosphere cultures and is associated with the proneural molecular subtype. Here, we report that Sox2 expression pattern in GBM tumors and patient-derived mouse xenografts is not restricted to a small percentage of cells and is coexpressed with various lineage markers, suggesting that its expression extends beyond CSCs to encompass more differentiated neoplastic cells across molecular subtypes. Employing a CSC derived from a patient with GBM and isogenic differentiated cell model, we show that Sox2 knockdown in the differentiated state abolished dedifferentiation and acquisition of CSC phenotype. Furthermore, Sox2 deficiency specifically impaired the astrocytic component of a biphasic gliosarcoma xenograft model while allowing the formation of tumors with sarcomatous phenotype.
    [Show full text]